pharmaceuticals3.28 min read
Oral GLP-1 Drugs Lead Obesity Treatment Revolution in $126B Market
1 year ago•Source: Clinical Trials Arena
Pharmaceuticals News
The latest pharmaceuticals stories, summarized by AI
Featured Pharmaceuticals Stories
View original source
2.485 min•1 year ago
AbbVie's Schizophrenia Drug Fails, Boosting Bristol Myers' Stock
AbbVie's $8.7 billion acquisition of Cerevel Therapeutics has hit a setback as its schizophrenia drug candidate, emraclidine, failed two phase 2 trials, missing primary endpoints and showing no significant improvement over placebo. This failure benefits rival Bristol Myers Squibb, whose stock rose as AbbVie's fell. Despite the setback, AbbVie notes other promising candidates from the Cerevel acquisition, including a Parkinson's disease treatment that recently succeeded in phase 3 trials.
More Top Stories
2
"Novo Nordisk Anticipates Wegovy Approval in China in 2022"
Seeking Alpha•1 year ago
3
"Viking Therapeutics' Breakthrough Weight-Loss Drug Challenges Pharma Giants"
Yahoo Finance•1 year ago
More Pharmaceuticals Stories
"Drug Makers Rush to Meet Demand Amid Concerns Over Catalent-Novo Deal Impact"
Novo Nordisk and Eli Lilly are racing to meet the high demand for their weight-loss drugs, Ozempic and Mounjaro, by investing heavily in manufacturing capacity. Novo Nordisk's unorthodox strategy involves acquiring Catalent, a contract manufacturer that serves the pharmaceutical industry, including Eli Lilly. Both companies are facing challenges in keeping up with demand, leading to customer frustration and shortages. The dueling medications, known as GLP-1 drugs, have the potential to become the biggest-selling class of all time, with annual sales projected to exceed $100 billion. Despite the manufacturing challenges, both companies are seeing significant financial success from their top-selling drugs.
"Pharma Giants Face Revenue Loss as Blockbuster Drugs Near Patent Expiry"
Big pharmaceutical companies like J&J, Merck, and Bristol Myers Squibb are facing a significant revenue threat as patents for their blockbuster drugs expire, allowing competitors to sell cheaper copycats. This could result in tens of billions of dollars in lost sales by 2030. Companies are preparing to offset these losses by building drug pipelines, making acquisitions, and entering partnerships. The looming patent cliffs and potential Medicare drug price negotiations pose challenges, but companies are exploring strategies such as developing new drug formulations and settling lawsuits to delay competition and extend patent protections.
"Bristol-Myers CEO Unveils Acquisition Strategy for Company's Future"
Bristol-Myers Squibb CEO Chris Boerner discussed the company's recent acquisitions, emphasizing a transformative phase and the infusion of innovation. The pharmaceutical giant plans to acquire RayzeBio, Mirati Therapeutics, and Karuna Therapeutics, with a focus on advancing cancer drugs and neuropsychiatric medications. Boerner highlighted the potential of Karuna's new medication, KarXT, in treating schizophrenia and psychosis in Alzheimer's patients, citing its efficacy and reduced side effects.
"Pharma Breakthroughs in 2023: Weight Loss, Alzheimer's, and Gene Editing"
In 2023, the pharmaceutical industry achieved significant milestones, including the rise of weight loss drugs as a lucrative market, the approval of the first drug to slow the progression of Alzheimer's disease, the rollout of the world's first vaccines against respiratory syncytial virus (RSV), and the approval of the first-ever gene-editing therapy for sickle cell disease. However, the demand for Covid vaccines and treatments declined, causing a financial burden on the industry. Additionally, the controversial Medicare drug price negotiations began, aiming to reduce prescription drug costs but facing opposition from pharmaceutical companies.
"Promising Results: Eli Lilly's Zepbound and Tirzepatide Revolutionize Obesity Treatment"
Eli Lilly's weight loss drug, Zepbound, has gained significant attention and media coverage since its FDA approval in November. The drug's availability in pharmacies has sparked further interest, fueled by discussions on social media about GLP-1s and off-label use of similar treatments.
Big Pharma's Battle: Sanofi Drops $750 Million Maze Deal Amidst FTC Antitrust Lawsuit
The pharmaceutical industry is facing a three-front battle with the Federal Trade Commission (FTC), Medicare, and the White House. The FTC is scrutinizing drug company deals to slow down growing monopolies in the pharma business. The White House is considering licensing drugs developed with federal funding to reduce costs, which has raised concerns about intellectual property rights. Medicare is targeting 10 drugs for price negotiations, leading to lawsuits from pharmaceutical companies. Experts believe that while these actions may send a message to the industry, the long-term odds of success are not great, and the legal system may ultimately decide the outcome.
Investor Misinterpretation: Eli Lilly's Positive Study Results
Despite a significant increase in its share price driven by strong sales of its diabetes drug Mounjaro and potential regulatory approval for Alzheimer's treatment donanemab, Eli Lilly is facing challenges in the long term. The hype around weight-loss drugs is declining, and competitors' drugs are showing higher weight-loss rates. This could negatively impact sales of Eli Lilly's diabetes medicines. The company's high valuation compared to competitors and its lowered earnings guidance for 2023 also raise concerns. As a result, the article recommends an "underperform" rating for Eli Lilly.
Decoding the Enigmatic Naming Process of Medications like Ozempic and Jardiance
The process of naming pharmaceutical drugs involves careful consideration of factors such as the number of letters and syllables, as well as the inclusion of specific letters like Z or X to make the name stand out. Jingles and catchy tunes in commercials help people remember the branded names of drugs. Research has shown that consumers are drawn to drugs with names starting with Z, which imparts a high-tech, sciency feeling. Sometimes the same drug has multiple names depending on its usage, and names are chosen to differentiate drugs with similar formulations. The naming process also involves creating a brand personality and considering the target audience.
Sanofi CEO showcases 12 blockbusters and increased R&D investment
Sanofi CEO Paul Hudson and company executives held an R&D day in Manhattan to address doubts about the company's ability to focus and execute, particularly in building a pipeline. Hudson touted 12 potential blockbusters and announced an increase in R&D spending, aiming to persuade skeptical investors.
"Merck KGaA's Evobrutinib Fails in Late-Stage Trials, Dealing Major Blow to MS Drug"
Merck KGaA's experimental multiple sclerosis drug, evobrutinib, has failed to meet its primary goal in late-stage trials, dealing a significant blow to the company's growth ambitions. The drug did not reduce the annualized relapse rate compared to Sanofi's Aubagio in patients with relapsing multiple sclerosis. Merck was considered ahead of competitors such as Sanofi, Novartis, and Roche in developing more targeted MS drugs known as Bruton's tyrosine kinase inhibitors. The failure of evobrutinib adds to Merck's recent setbacks, including the discontinuation of its cancer drug bintrafusp alfa and weak demand for specialty materials.